Q-omics provides the consensus-scored RPL7AP53 profile across patient tissues and cancer cell-line models. RPL7AP53 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL7AP53 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, RPL7AP53 RNA expression shows 12,452 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where RPL7AP53 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL7AP53 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL7AP53 survival associations across molecular data types. RPL7AP53 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL7AP53 RNA expression–survival associations across cancer types. High RPL7AP53 expression shows unfavorable associations in ACC, UVM and OV, but favorable associations in SKCM, CESC and MESO. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL7AP53 RNA expression.
This table summarizes RPL7AP53 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL7AP53. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL7AP53 shows lower tumor expression in BRCA and higher tumor expression in COAD, KIRC, LIHC, LUAD and THCA. The COAD box plot shows higher RPL7AP53 RNA expression in tumor versus normal tissue (log2 FC = +0.304, t-test p < 0.001).
This table shows molecular features associated with RPL7AP53 in patient tissues and cancer cell lines. In patient samples, RPL7AP53 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
